The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule. 178
What this version reported
FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗
Trial records: NCT07437547
Reader guide in this version
Key takeaway
BPC-157 is a 15-amino-acid peptide first described by researchers in 1993, and most research on it has been done in rodents and laboratory models.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved medicine containing it in any country it searched.1 Published human data are limited to a few small, short studies. FDA concluded they do not show that it works for the one use it evaluated, ulcerative colitis, and are not enough to describe its safety.1 FDA staff recommended against adding BPC-157 to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides that licensed pharmacies may compound under set conditions without federal enforcement action while FDA’s rulemaking continues.1,7,8
At a glance
- What it is
- A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1
- FDA status
- Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,7,8
- Human evidence
- A few small, short human studies, including one randomized ulcerative colitis study reported only as a meeting abstract. Two registered trials had no posted results in the cited registry records.1,3,5
- Sport status
- FDA’s briefing notes that BPC-157 is on the World Anti-Doping Agency’s prohibited list under non-approved substances (S0), as FDA checked in December 2025.1
- Evidence strength
- Limited human data
What is BPC-157?
BPC-157 is a peptide made of 15 amino acids. FDA’s briefing describes it as a fragment of a larger protein, called body protection compound, that was originally isolated from human gastric juice. It is also known as bepecin or PL 14736.1
Researchers first described BPC-157 in 1993 and have studied it mainly for proposed protective and healing effects in animals. FDA could not determine how long it has been used in pharmacy compounding.1
FDA found BPC-157 marketed in the United States as an ingredient in dietary supplement products, and found that websites promoting it most often mention digestive uses.1
How is BPC-157 thought to work?
How BPC-157 works has not been established. FDA’s briefing states that its molecular targets have not been identified and that its mechanisms of action remain poorly understood.1
Based on animal and laboratory studies, researchers have proposed that it may increase growth-factor signaling, reduce inflammatory signals, promote new blood-vessel formation, and raise nitric oxide production.1
FDA cautions that these animal findings should be interpreted carefully, because larger amounts did not produce consistently larger effects and the biological plausibility of the reported effects is hard to assess.1
What do human studies show?
FDA’s 2026 review identified five published human studies. All were small and short, and FDA found that their authors provided limited safety information.1
The only randomized, placebo-controlled study FDA found tested a BPC-157 enema for two weeks in 53 people with ulcerative colitis. It was reported only as a 2005 meeting abstract, and FDA concluded its data were inadequate to support efficacy or safety.1
No serious adverse events appear to have been reported in these studies, but FDA notes that safety monitoring was unclear for most of them. FDA found no human studies using the oral, under-the-skin, nasal or skin routes proposed for compounded products.1
FDA’s adverse-event reports include injection-site reactions, shortness of breath, and darkening of the skin and gums after BPC-157 use, but FDA could not determine whether BPC-157 caused them.1
Two newer trials are registered: a Phase 2 hamstring-strain trial and a Phase 1 rotator cuff study. Neither had posted results in the cited registry records.3,5
What the evidence base contains
- Small, short, or incompletely reported human study One randomized, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract. FDA found its reported details inadequate to support efficacy or safety conclusions.1
- Small, short, or incompletely reported human study Four other small human reports listed by FDA: enema studies in healthy volunteers, knee-pain injections in 17 people, bladder injections in 12 people with interstitial cystitis, and an intravenous safety pilot in two healthy adults.1
- Registered trial without results A randomized Phase 2 trial in adults with an acute hamstring strain, first posted in February 2026 as recruiting, with no results posted.3
- Registered trial without results A Phase 1 study in rotator cuff tears, listed as not yet recruiting in its September 3, 2026 registry record.5
- Animal or laboratory research Most published research reports effects in rodent and laboratory models, including gut, liver, tendon and nerve injury models.1
Evidence-strength label: Limited human data. How this label is assigned
Is BPC-157 FDA-approved?
No. FDA’s May 2026 evaluation states that BPC-157 is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.7
FDA staff evaluated BPC-157 for that list for ulcerative colitis and recommended against adding it. They cited poor chemical characterization, limited safety information, a risk of immune reactions, insufficient evidence of effectiveness, and existing FDA-approved treatments for ulcerative colitis.1
FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.2
FDA’s Pharmacy Compounding Advisory Committee discussed BPC-157 at its July 23–24, 2026 meeting. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,4,8
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS says the policy is not binding and may be revisited if safety or quality problems arise.7
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.8
The policy does not make BPC-157 an FDA-approved drug. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.8
Timeline
- Researchers first describe BPC-157 in the scientific literature.1
- A Federal Register notice announces the July advisory-committee meeting that will discuss BPC-157 and opens a public comment docket.6
- FDA’s compounding safety-risk page, as last updated, lists BPC-157 among withdrawn nominations and describes immune-reaction and characterization concerns.2
- FDA staff date their evaluation recommending that BPC-157 not be added to the 503A bulks list.1
- FDA’s Pharmacy Compounding Advisory Committee discusses BPC-157.4
- HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists BPC-157 among six peptide substances used in compounding.7,8
What is still unknown?
Whether BPC-157 benefits people for any condition: none of the human studies FDA identified was a fully reported controlled trial.1
Its safety with repeated or long-term use, and how much reaches the bloodstream after oral, injected, nasal or skin use, have not been established in people.1
What is actually in products sold under the name: FDA notes that the free base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1
Whether FDA’s rulemaking will add BPC-157 to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,7,8
Sources for this version
- 1FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 4July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 5ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 6Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026
- 7Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026